Product image of Icalziss (Calcium Chloride Dihydrate) supplied by GNH India

Icalziss

Active Ingredient:
Calcium Chloride Dihydrate
Origin:
EU

Icalziss (Calcium Chloride Dihydrate)

Calcium chloride dihydrate, the active ingredient in Icalziss, is a calcium salt presented as an intravenous solution for extracorporeal use. It is employed to correct low blood calcium levels and to provide calcium supplementation during dialysis procedures. The formulation is sterile, isotonic and compatible with standard infusion sets, allowing precise titration of calcium ions under clinical supervision.

GNH India supplies Icalziss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and dialysis clinics worldwide, ensuring quality‑controlled manufacturing and reliable logistics for critical care settings.

Manufacturer / TM Owner

Vantive Belgium

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icalziss is used to manage disorders of calcium balance and to support patients undergoing renal replacement therapy.

  • Hypocalcemia: restores normal serum calcium concentrations in patients with low calcium levels.
  • Dialysis-associated calcium deficiency: provides calcium supplementation during hemodialysis to maintain electrolyte stability.
  • Perioperative calcium depletion: helps maintain calcium homeostasis during surgeries that may cause calcium loss.

How It Works

  • Calcium chloride dihydrate dissociates in plasma to release calcium ions (Ca2+). The increased extracellular calcium concentration enhances calcium‑dependent physiological processes, including myocardial contractility, neurotransmission, and blood coagulation. By raising serum calcium levels, the solution corrects hypocalcemia and supplies the calcium required during dialysis, where calcium loss can occur through the dialysate. The administered calcium integrates into the body's calcium pool, contributing to bone mineralization and enzymatic activity.

Side Effects

Calcium chloride dihydrate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Infusion site irritation: redness or pain at the injection site.
  • Transient hypercalcemia: temporary elevation of serum calcium levels.
  • Hypotension: drop in blood pressure during rapid infusion.
  • Nausea or vomiting: gastrointestinal discomfort.

Serious or Rare Side Effects

  • Severe hypercalcemia: can lead to cardiac arrhythmias or renal impairment.
  • Cardiac arrest: rare but possible with rapid high‑dose administration.
  • Tissue necrosis: extravasation may cause local tissue damage.
  • Anaphylactic reaction: rare hypersensitivity requiring immediate treatment.

Precautions & Warnings

When using Icalziss, clinicians should observe several safety measures to minimize risks.

  • Serum calcium monitoring: check calcium levels before and during infusion.
  • Renal function assessment: adjust dosing in patients with impaired kidney function.
  • Cardiac status evaluation: observe for arrhythmias, especially in patients with heart disease.
  • Concurrent blood product infusion: avoid mixing with blood components to prevent precipitation.
  • Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Calcium chloride dihydrate can interact with several medications, influencing calcium balance or drug efficacy.

Major Interactions (Avoid)

  • Loop diuretics: increase urinary calcium loss, potentially counteracting therapy.
  • Bisphosphonates: may precipitate severe hypocalcemia when given concurrently.
  • Calcitonin: additive calcium‑lowering effect, risking hypocalcemia.

Moderate Interactions (Monitor Closely)

  • Digitalis glycosides: elevated calcium may enhance digitalis toxicity.
  • ACE inhibitors: monitor blood pressure as calcium can affect vascular tone.
  • Magnesium sulfate: concurrent use may alter calcium homeostasis.

Frequently Asked Questions

Icalziss is an intravenous calcium chloride dihydrate solution used primarily to treat hypocalcemia and to provide calcium supplementation during hemodialysis or other renal replacement therapies where calcium loss can occur.

When administered, calcium chloride dihydrate dissociates into calcium ions that raise extracellular calcium concentrations. This supports calcium‑dependent processes such as cardiac contractility, nerve transmission, and blood coagulation, thereby correcting low serum calcium levels.

The dose of Icalziss is individualized. A prescriber determines the amount and infusion rate based on the patient’s serum calcium level, clinical condition, and response to therapy, following local guidelines and monitoring protocols.

Safety data for calcium chloride dihydrate in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Icalziss, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Icalziss delivers calcium as calcium chloride, which provides a higher elemental calcium concentration per millilitre than calcium gluconate. This allows rapid correction of severe hypocalcemia, but it also requires careful monitoring to avoid hypercalcemia. Oral calcium salts are slower acting and used for chronic supplementation.

Icalziss should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution. Before use, inspect for particulate matter and ensure the vial is within its expiry date.

Icalziss is administered intravenously, typically via a peripheral or central line. The infusion rate is adjusted by the clinician to avoid rapid calcium spikes, often diluted in compatible IV fluids and given over several minutes, with continuous monitoring of vital signs and serum calcium.

Serious risks include severe hypercalcemia, which can cause cardiac arrhythmias, myocardial ischemia, or renal failure, as well as tissue necrosis if the solution extravasates. Rarely, anaphylactic reactions may occur, requiring immediate emergency treatment.

Icalziss is contraindicated in patients with known hypercalcemia, severe renal impairment where calcium clearance is compromised, and in those with a history of hypersensitivity to calcium chloride. Caution is also advised for patients with existing cardiac conduction abnormalities.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Calcium Chloride Dihydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT